drugset / Trial / NCT01047839
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The primary objective is to assess the safety profile of IC51 in a pediatric population from regions where JEV is not endemic
Timeline
- Start
- 2010-01
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IC51 | Vaccine | 0.25 ml | Intramuscular |
| Subject | IC51 | Vaccine | 0.5 ml | Intramuscular |